Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women.
Holcomb K, Vucetic Z, Miller MC, Knapp RC.
Am J Obstet Gynecol. 2011 Oct;205(4):358.e1-6. Epub 2011 May 14.
Related citations
A regressive Meigs syndrome after definitive adnexal torsion.
Rousset P, Chaillot PF, Bats AS, Le Frère Belda MA, Buy JN.
Am J Obstet Gynecol. 2011 Oct;205(4):e4-5. Epub 2011 Apr 16.
Anti-N-methyl-D-aspartate receptor encephalitis complicating ovarian teratomas: a case report.
Naoura I, Didelot A, Walker F, Luton D, Koskas M.
Am J Obstet Gynecol. 2011 Oct;205(4):e6-8. Epub 2011 May 10.
New drugs for ovarian cancer.
Bell-McGuinn K, Konner J, Tew W, Spriggs DR.
Ann Oncol. 2011 Dec;22 Suppl 8:viii77-viii82. Review. No abstract available.
Update on PARP1 inhibitors in ovarian cancer.
Sessa C.
Ann Oncol. 2011 Dec;22 Suppl 8:viii72-viii76.
The use of bevacizumab in the management of ovarian cancer: an argument for single-agent rather than combination therapy.
Markman M.
Ann Oncol. 2011 Dec;22 Suppl 8:viii69-viii71.
Antiangiogenic agents should be integrated into the standard treatment for patients with ovarian cancer.
Burger RA.
Ann Oncol. 2011 Dec;22 Suppl 8:viii65-viii68.
Designing early detection programs for ovarian cancer.
Urban N.
Ann Oncol. 2011 Dec;22 Suppl 8:viii6-viii18.
Molecular approaches to personalizing management of ovarian cancer.
Bast RC Jr.
Ann Oncol. 2011 Dec;22 Suppl 8:viii5-viii15. Review.
Optimal assessment of response in ovarian cancer.
Eisenhauer EA.
Ann Oncol. 2011 Dec;22 Suppl 8:viii49-viii51.
Follow-up with CA125 after primary therapy of advanced ovarian cancer has major implications for treatment outcome and trial performances and should not be routinely performed.
Rustin GJ.
Ann Oncol. 2011 Dec;22 Suppl 8:viii45-viii48.
Follow-up with CA125 after primary therapy of advanced ovarian cancer: in favor of continuing to prescribe CA125 during follow-up.
Pignata S, Cannella L, Leopardo D, Bruni GS, Facchini G, Pisano C.
Ann Oncol. 2011 Dec;22 Suppl 8:viii40-viii44.
Dose-dense therapy is of benefit in primary treatment of ovarian cancer: contra.
van der Burg ME, Boere IA, Berns PM.
Ann Oncol. 2011 Dec;22 Suppl 8:viii33-viii39.
Dose-dense therapy is of benefit in primary treatment of ovarian cancer? In favor.
Katsumata N.
Ann Oncol. 2011 Dec;22 Suppl 8:viii29-viii32. Review.
To predict or not to predict? The dilemma of predicting the risk of suboptimal cytoreduction in ovarian cancer.
Kang S, Park SY.
Ann Oncol. 2011 Dec;22 Suppl 8:viii23-viii28.
Quality control in ovarian cancer surgery.
Hacker NF.
Ann Oncol. 2011 Dec;22 Suppl 8:viii19-viii22. Review.
Pharmacologic and phenotypic study of docetaxel in patients with ovarian or primary peritoneal cancer.
Zamboni WC, Combest AJ, DeLoia JA, Edwards RP, Bridges AS, Zamboni BA, Walko CM, Yu AY, Krivak TC, Kelley JL.
Cancer Chemother Pharmacol. 2011 Nov;68(5):1255-62. Epub 2011 Mar 25.
Dopamine blocks stress-mediated ovarian carcinoma growth.
Moreno-Smith M, Lu C, Shahzad MM, Pena GN, Allen JK, Stone RL, Mangala LS, Han HD, Kim HS, Farley D, Berestein GL, Cole SW, Lutgendorf SK, Sood AK.
Clin Cancer Res. 2011 Jun 1;17(11):3649-59. Epub 2011 Apr 29.
Longitudinal evaluation of CA-125 velocity and prediction of ovarian cancer.
Xu JL, Commins J, Partridge E, Riley TL, Prorok PC, Johnson CC, Buys SS.
Gynecol Oncol. 2012 Apr;125(1):70-4. Epub 2011 Dec 22.
The "luxury" of second malignancies.
Armstrong DK, Visvanathan K.
Gynecol Oncol. 2011 Dec;123(3):453-4. Epub 2011 Oct 11. No abstract available.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on